Pregnancy With Glanzmann Thrombasthenia: What a Study of 173 Pregnancies Found

Pregnancy and childbirth can present additional challenges for women with Glanzmann Thrombasthenia (GT), a rare inherited bleeding disorder. A 2025 study published in the British Journal of Hematology examined 173 pregnancies to better understand bleeding risks, complications, and treatment approaches.

The findings highlight the importance of planning while also showing that women with GT can have successful pregnancies and deliveries.

What Did the Study Find?

Researchers reviewed previously published studies and case reports involving 173 pregnancies. They also presented experiences from eight women receiving care at three European treatment centers.

Key findings included:

• 60% experienced postpartum hemorrhage among 145 deliveries with reported bleeding outcomes.
• 22% of babies had reported complications, including bleeding and low platelet counts.
• The miscarriage rate was 15%, comparable to the general population.
• 53% of documented deliveries were vaginal births, while 47% were C-sections.

These numbers reflect published cases, which may include a higher proportion of complicated pregnancies. They should not be interpreted as the exact risk for every woman with GT.

Why Are Platelet Antibodies Important During Pregnancy?

Some women with Glanzmann Thrombasthenia develop antibodies against platelets, sometimes following platelet transfusions or during pregnancy.

These antibodies can affect treatment options and, in some cases, cross the placenta, causing dangerously low platelet counts in the baby.

The researchers found an association between maternal platelet antibodies and newborn complications, emphasizing the importance of antibody screening and monitoring.

Can Women With GT Have a Safe Delivery?

Yes. Both vaginal births and C-sections were reported in the study, including deliveries resulting in healthy babies.

However, bleeding can occur during delivery or several weeks afterward. Treatment approaches included platelet transfusions, tranexamic acid, and recombinant activated factor VII (rFVIIa).

The researchers could not determine which preventive treatment approach works best because care varied considerably between cases.

They recommend that women with GT receive coordinated care from hematologists and obstetric specialists experienced with bleeding disorders.

What Does This Mean for Women With GT?

The study reinforces three important points:

1. Plan early. Discuss pregnancy and delivery with a specialized medical team.
2. Monitor platelet antibodies. Screening may help identify potential risks to the baby.
3. Prepare for postpartum bleeding. Bleeding risks can continue after leaving the hospital.

Every person with Glanzmann Thrombasthenia experiences the condition differently. Care should be guided by individual bleeding history, platelet antibodies, and other medical factors.

More Research Is Needed

Researchers concluded that pregnancy management in GT remains inconsistent and that larger international studies and clearer treatment guidelines are needed.

This article is for educational purposes and does not replace individualized medical advice.